B. Metzler seel. Sohn & Co. Holding AG Makes New Investment in Medpace Holdings, Inc. (NASDAQ:MEDP)

B. Metzler seel. Sohn & Co. Holding AG bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) in the third quarter, HoldingsChannel reports. The fund bought 9,280 shares of the company’s stock, valued at approximately $3,098,000.

Several other hedge funds have also modified their holdings of MEDP. O Shaughnessy Asset Management LLC acquired a new stake in Medpace in the first quarter valued at approximately $307,000. Natixis purchased a new position in shares of Medpace in the first quarter valued at $727,000. MQS Management LLC purchased a new position in shares of Medpace in the first quarter valued at $318,000. EntryPoint Capital LLC acquired a new stake in Medpace during the 1st quarter valued at $54,000. Finally, CreativeOne Wealth LLC purchased a new stake in Medpace during the 1st quarter worth $1,304,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Baird R W lowered Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Jefferies Financial Group downgraded Medpace from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $415.00 to $345.00 in a report on Wednesday, September 25th. Redburn Atlantic began coverage on Medpace in a research note on Monday, October 14th. They set a “buy” rating and a $404.00 target price for the company. TD Cowen dropped their price target on shares of Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. Finally, UBS Group downgraded shares of Medpace from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $420.00 to $350.00 in a research note on Friday, September 27th. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $380.00.

Medpace Price Performance

MEDP stock opened at $326.09 on Thursday. The firm has a fifty day moving average price of $340.65 and a two-hundred day moving average price of $374.33. Medpace Holdings, Inc. has a 1-year low of $268.80 and a 1-year high of $459.77. The firm has a market cap of $10.13 billion, a price-to-earnings ratio of 28.55, a PEG ratio of 1.72 and a beta of 1.37.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.24. The firm had revenue of $533.32 million for the quarter, compared to analyst estimates of $540.99 million. Medpace had a net margin of 17.66% and a return on equity of 50.87%. Medpace’s quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.22 earnings per share. As a group, analysts expect that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.